When will the LANTIDRA patents expire, and when will biosimilar LANTIDRA be available?

Last updated: September 22, 2026

Lantidra, the brand name for donislecel, is the first FDA-approved allogeneic pancreatic islet cellular therapy. FDA approved it on June 28, 2023, for adults with type 1 diabetes who cannot achieve adequate glycemic control because of current repeated severe hypoglycemia despite intensive diabetes management and education.[1] Its commercial opportunity is concentrated in a small, high-risk patient population, while donor-organ supply, immunosuppression requirements, specialized administration, and reimbursement create substantial limits on near-term adoption.

CellTrans Inc. owns and commercializes Lantidra. Public financial disclosures do not provide a reliable product-level revenue history or consensus sales forecast. The commercial trajectory is therefore best assessed through eligible-patient volume, treatment-center capacity, pricing and reimbursement, donor supply, and competition from stem-cell-derived islet therapies.

What is Lantidra and which patients can receive it?

Lantidra is an allogeneic pancreatic islet cellular therapy manufactured from deceased-donor pancreatic tissue. The product is infused into the hepatic portal vein, where transplanted islet cells can produce insulin.

FDA-approved use is limited to adults who:

Have type 1 diabetes.
Are unable to approach target glycated hemoglobin because of repeated severe hypoglycemia.
Continue to experience severe hypoglycemia despite intensive diabetes management and education.
Are suitable candidates for chronic immunosuppression.

Lantidra is not an insulin-replacement product for the general type 1 diabetes population. It is a rescue therapy for patients with brittle diabetes, impaired hypoglycemia awareness, or severe hypoglycemia that persists despite optimized insulin delivery and glucose monitoring.

The pivotal evidence was based on 30 participants. Ten participants did not require insulin for one to five years after treatment. Eleven achieved insulin independence for one to five years before restarting insulin. Nine participants never achieved insulin independence.[1]

What are the principal clinical limitations?

The principal limitations are:

Limitation	Commercial effect
Chronic immunosuppression	Excludes patients unable to tolerate transplant immunosuppression
Donor-derived tissue	Limits manufacturing scale and batch availability
Portal-vein infusion	Requires specialized transplant or interventional expertise
Variable durability	Reduces certainty of long-term insulin independence
Serious adverse-event risk	Increases clinical screening and monitoring requirements
Small eligible population	Restricts total addressable revenue

Reported risks include procedural complications, immunosuppression-related infections and malignancies, renal impairment, anemia, and portal-vein thrombosis.[1]

How large is the Lantidra market?

Lantidra addresses a narrow segment of the type 1 diabetes market rather than the full insulin or continuous glucose monitoring market.

The relevant population includes adults with recurrent severe hypoglycemia despite intensive therapy. The total number of people with type 1 diabetes in the United States is measured in the millions, but only a small subset is likely to satisfy all Lantidra criteria and remain eligible after assessment of renal function, malignancy risk, infection risk, adherence, and immunosuppression tolerance.

The commercial market has four structural constraints:

Severe hypoglycemia must remain uncontrolled despite modern insulin delivery and glucose monitoring.
Patients must accept lifelong immunosuppression.
Treatment must occur at specialized centers.
Donor pancreata must be available and suitable for islet isolation.

These constraints make Lantidra a high-value, low-volume therapy. Its revenue potential depends more on treatment capacity and reimbursement than on broad disease prevalence.

What is the Lantidra financial trajectory?

CellTrans has not publicly disclosed a detailed Lantidra sales series, product-level revenue target, or publicly traded financial model. The launch is therefore more likely to follow a capacity-constrained specialty-cell-therapy trajectory than the rapid uptake associated with mass-market diabetes drugs.

Commercial trajectory by phase

Period	Likely commercial condition	Main value driver
2023-2024	Launch and center activation	FDA approval, clinical education, reimbursement negotiations
2025-2027	Selective expansion	More qualified centers and payer coverage
2028-2030	Capacity optimization	Donor procurement, manufacturing throughput, repeat treatment
2031-2035	Competitive pressure increases	Stem-cell-derived islet products and manufacturing alternatives
After 2035	Potential loss of core biologic exclusivity	Follow-on cellular products and improved technologies

Near-term revenue is likely to be limited by the number of procedures that can be performed, not simply by patient demand. A therapy based on donor pancreata cannot scale like a conventional biologic produced in a large bioreactor.

What determines Lantidra revenue?

A simplified revenue model is:

Revenue = treated patients x net treatment price x repeat-treatment frequency

The most important variables are:

Number of transplant centers able to administer Lantidra.
Number of donor pancreata available for manufacturing.
Payer willingness to reimburse the product and procedure.
Hospital payment treatment for portal-vein infusion and monitoring.
Duration of insulin independence.
Use of Lantidra as a one-time treatment versus repeat treatment.
Patient attrition caused by immunosuppression or adverse events.

Public information does not establish a verified Lantidra wholesale acquisition cost. Net revenue would also depend on payer discounts, hospital contracts, treatment-center economics, and whether the product is reimbursed separately from the procedure.

What is the FDA regulatory status of Lantidra?

Lantidra received FDA approval through the Center for Biologics Evaluation and Research as a cellular therapy product.[1] It is not a conventional small-molecule drug and is not a monoclonal antibody.

Regulatory item	Status
Product	Lantidra
Active therapy	Donislecel, allogeneic pancreatic islets
Sponsor/manufacturer	CellTrans Inc.
FDA approval	June 28, 2023
Regulator	FDA, Center for Biologics Evaluation and Research
Disease	Type 1 diabetes with recurrent severe hypoglycemia
Administration	Portal-vein infusion
Pediatric approval	Not established
Chronic immunosuppression	Required
Biosimilar pathway	Not directly applicable

Lantidra carries extensive warnings and requires patient selection, immunosuppressive management, and post-treatment monitoring. The label does not support use as a broad substitute for insulin therapy.

When does Lantidra lose exclusivity?

Lantidra is a licensed biologic and may receive the statutory 12-year reference-product exclusivity period under the Public Health Service Act, subject to the rules governing first licensure and any applicable regulatory determinations. Based on the June 28, 2023 approval date, the reference-product exclusivity period would generally extend to approximately June 28, 2035.[2]

This date is not equivalent to a guaranteed generic or follow-on launch date. A competing product would still require FDA approval through an applicable biologics pathway and would need to overcome manufacturing, comparability, clinical, and supply-chain requirements.

What is the Orange Book status of Lantidra?

Lantidra is not expected to have the same Orange Book patent-listing profile as a conventional small-molecule drug. The Orange Book primarily identifies approved drug products and patents relevant to certain abbreviated new drug applications. Lantidra is regulated as a biologic cellular therapy, so its principal regulatory exclusivity framework is the Public Health Service Act and the Biologics Price Competition and Innovation Act rather than the standard Hatch-Waxman Orange Book pathway.[2,3]

Patent rights may still cover:

Islet isolation and purification.
Cell-processing methods.
Preservation and transport.
Formulations and cryopreservation.
Portal-vein delivery systems.
Donor-tissue processing.
Quality-control and release testing.
Manufacturing know-how.

The existence, scope, and enforceability of any relevant patent portfolio must be evaluated through issued patents, pending applications, ownership records, prosecution history, and freedom-to-operate analysis. FDA approval alone does not establish patent protection.

What patents protect Lantidra?

Publicly available regulatory information does not establish a comprehensive, verified patent list specifically covering Lantidra or donislecel. Unlike a conventional branded drug, the core competitive barrier may lie as much in biological material, manufacturing know-how, donor procurement, clinical operations, and regulatory controls as in composition-of-matter patents.

The likely IP layers are:

IP layer	Relevance to Lantidra
Composition claims	May be difficult if the product consists of naturally derived donor islets
Manufacturing claims	Could cover isolation, purification, culture, formulation, or release testing
Process controls	May protect viability, potency, purity, and sterility methods
Delivery claims	Could cover administration or infusion systems
Trade secrets	Likely important for donor selection, processing, and manufacturing yields
Regulatory exclusivity	Provides a defined barrier independent of patent scope

A competing allogeneic islet product may avoid infringement by using a different donor source, isolation procedure, cell composition, preservation method, or delivery process. This makes process and manufacturing patents more important than a single broad composition patent.

Are there Paragraph IV challenges to Lantidra?

A conventional Paragraph IV challenge is unlikely to be the primary route for competing with Lantidra because Paragraph IV litigation is associated with patents listed for small-molecule products in the Orange Book. Lantidra is a biologic cellular therapy, and follow-on developers would generally use the biologics framework rather than an ANDA-based generic pathway.[2,3]

Potential future competition would more likely involve:

A biosimilar or interchangeable biological product, if the product and regulatory pathway were considered appropriate.
A distinct cell therapy with a new biologic license application.
A stem-cell-derived islet product.
A device-enabled encapsulated islet product.
A gene-edited or immune-evasive cell product.

No publicly established Lantidra Paragraph IV litigation or settlement agreement is identified in the FDA approval materials cited here.

How strong is the Lantidra patent estate?

The commercial protection profile appears stronger in regulatory and operational barriers than in publicly demonstrated patent breadth.

Relative strength of protection

Protection type	Assessment
FDA biologic exclusivity	High through the statutory exclusivity period, subject to applicable rules
Donor supply	High barrier, but not necessarily exclusive
Specialized manufacturing	High operational barrier
Clinical evidence	Moderate barrier because competitors need safety and efficacy data
Procedure and center network	Moderate barrier
Composition-of-matter patent protection	Not established from the cited public regulatory materials
Trade secrets	Potentially significant
Biosimilar substitution risk	Low in the near term
Stem-cell-derived competition	Increasing over time

Lantidra's defensibility depends on whether CellTrans can secure donor supply, maintain manufacturing consistency, establish payer coverage, and develop a treatment-center network before alternative islet technologies mature.

Which companies are challenging Lantidra competitively?

The most relevant competitive threats are not traditional insulin manufacturers. They are developers of implantable or infused insulin-producing cell therapies.

Vertex Pharmaceuticals

Vertex's stem-cell-derived islet programs, including VX-880, now known as zimislecel, target insulin production without reliance on deceased-donor pancreatic islets. The program is intended to address type 1 diabetes with severe hypoglycemia and may compete directly with Lantidra if it achieves regulatory approval and reduces or eliminates chronic immunosuppression requirements.[4]

Vertex has also evaluated encapsulated cell approaches, including VX-264, designed to protect insulin-producing cells from immune attack. A successful device-based approach could reduce the need for systemic immunosuppression and expand the eligible population.

Sernova

Sernova has developed a cell-pouch platform intended to house insulin-producing cells and support vascularization. Its approach represents a potential alternative delivery system rather than a direct donor-islet replica.[5]

Other cell-therapy developers

Academic groups and biotechnology companies are developing:

Stem-cell-derived pancreatic endoderm.
Gene-edited immune-evasive islet cells.
Encapsulated islet devices.
Xenogeneic islet products.
Improved donor-islet transplantation protocols.

These programs face their own barriers, including tumorigenicity, immune rejection, engraftment, manufacturing consistency, device durability, and regulatory classification.

What manufacturing and geographic barriers affect Lantidra?

Lantidra's geographic reach is constrained by donor tissue, processing infrastructure, and administration capability.

Manufacturing barriers

The product depends on:

Procurement of suitable deceased-donor pancreata.
Rapid transport to a processing facility.
Islet isolation and purification.
Potency, purity, sterility, and viability testing.
Controlled distribution to treatment centers.
Coordinated portal-vein administration.

The supply chain is more complex than that of recombinant insulin or an antibody manufactured in standardized large-scale batches.

Geographic coverage

Near-term use is likely to concentrate in major U.S. transplant and diabetes centers with:

Interventional radiology or transplant surgery capability.
Experience with portal-vein procedures.
Endocrinology and transplant-immunology support.
Intensive post-treatment monitoring.
Payer contracting capacity.

International expansion would require country-specific regulatory approvals, donor-tissue rules, hospital infrastructure, and reimbursement negotiations. Europe, Canada, Japan, and Australia may require separate regulatory submissions and local manufacturing or import controls.

What generic launch risks exist for Lantidra?

The risk of a conventional low-cost generic launch is low. The meaningful threat is substitution by a different cellular therapy.

Near-term risk: low

Lantidra has a first-mover position, regulatory approval, clinical experience, and a defined treatment pathway. Competitors cannot immediately reproduce its supply chain or secure approval through a simple generic application.

Medium-term risk: moderate

Risk increases if:

Stem-cell-derived islet products demonstrate durable insulin independence.
Immunosuppression is reduced or eliminated.
Manufacturing costs fall.
Treatment can be delivered through a simpler procedure.
Payers prefer scalable products with predictable supply.
Competitors obtain stronger clinical evidence in larger populations.

Long-term risk: high

By the early-to-mid 2030s, Lantidra may face products with superior cell sources, better durability, lower immunosuppression burden, and more scalable manufacturing. Its commercial position will depend on whether it remains the only approved option for patients needing immediate treatment or becomes an older platform displaced by renewable cell sources.

How does Lantidra compare with competing diabetes therapies?

Therapy	Main advantage	Main limitation	Competitive position
Lantidra	Approved donor-islet cellular therapy	Donor supply and chronic immunosuppression	Current approved cellular option
Intensive insulin therapy	Widely available and scalable	Does not eliminate severe hypoglycemia in all patients	Standard of care
Continuous glucose monitoring	Improves detection and prevention	Does not restore endogenous insulin production	Reduces eligible population
Insulin pumps and automated delivery	Improves glucose control	Residual severe hypoglycemia risk	Indirect competitor
Pancreas transplant	Can restore endogenous insulin production	Major surgery and immunosuppression	Alternative for selected patients
Stem-cell-derived islet therapy	Potentially scalable	Clinical and regulatory development risk	Main future threat
Encapsulated islet devices	Potentially lower systemic immunosuppression	Device durability and engraftment challenges	Emerging alternative

Key Takeaways

Lantidra is the first FDA-approved allogeneic pancreatic islet cellular therapy.
Its target market is a narrow group of adults with type 1 diabetes and persistent severe hypoglycemia despite intensive management.
CellTrans has not publicly reported a detailed Lantidra revenue history or validated product-level sales forecast.
Revenue growth is likely to be constrained by donor supply, specialized treatment centers, reimbursement, and chronic immunosuppression.
The product's principal near-term protection is regulatory approval combined with manufacturing and clinical-operational barriers.
Lantidra is not a conventional Orange Book small-molecule product, and Paragraph IV litigation is not expected to be the central competitive pathway.
The relevant future competitors are stem-cell-derived and encapsulated islet therapies, particularly programs designed to reduce or eliminate immunosuppression.
Statutory biologic exclusivity based on the 2023 approval date could extend approximately through June 2035, subject to applicable first-licensure and regulatory rules.
Long-term value depends on whether donor-derived islets remain clinically useful after renewable cell sources become available.

FAQs

Is Lantidra a cure for type 1 diabetes?

No. Lantidra can restore insulin production in some patients and may produce periods of insulin independence, but it does not eliminate the underlying autoimmune disease or the need for chronic immunosuppression.

How long does Lantidra insulin independence last?

In the FDA-reviewed clinical data, some participants remained insulin-independent for one to five years. Others later resumed insulin, and some never achieved insulin independence.[1]

Does Lantidra require lifelong immunosuppression?

Yes. Chronic immunosuppression is required to protect the transplanted allogeneic islet cells, creating substantial eligibility and safety limitations.[1]

Can Lantidra be replaced by a generic drug?

A conventional generic substitution is unlikely. Any meaningful competitor would more likely be another biologic or cellular therapy requiring its own regulatory approval.

What is the biggest commercial risk to Lantidra?

The largest long-term risk is displacement by scalable stem-cell-derived or encapsulated islet therapies that provide durable insulin production with less dependence on deceased-donor tissue and systemic immunosuppression.

References

U.S. Food and Drug Administration. (2023). FDA approves first cellular therapy to treat patients with type 1 diabetes. https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-type-1-diabetes
U.S. Food and Drug Administration. (2024). Regulatory information: Biosimilar and interchangeable products. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
Vertex Pharmaceuticals Incorporated. (2024). Type 1 diabetes program. https://www.vrtx.com/our-science/pipeline/
Sernova Corp. (2024). Cell pouch system and type 1 diabetes clinical program. https://www.sernova.com/

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Summary for Tradename: LANTIDRA

Note on Biologic Patents

1) High Certainty: US Patents for LANTIDRA Derived from Brand-Side Litigation

2) High Certainty: US Patents for LANTIDRA Derived from DrugPatentWatch Analysis and Company Disclosures

3) Low Certainty: US Patents for LANTIDRA Derived from Patent Text Search